Literature DB >> 19696417

Inflammatory biomarkers of vascular risk as correlates of leukoariosis.

Clinton B Wright1, Yeseon Moon, Myunghee C Paik, Truman R Brown, LeRoy Rabbani, Mitsuhiro Yoshita, Charles DeCarli, Ralph Sacco, Mitchell S V Elkind.   

Abstract

BACKGROUND AND
PURPOSE: Inflammatory biomarkers, including lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), and high-sensitivity C-reactive protein (hsCRP) are associated with ischemic stroke risk. White matter hyperintensities (WMH) seen on brain MRI scans are associated with vascular risk factors and an increased risk of incident stroke, but their relation to inflammatory biomarkers is unclear.
METHODS: The Northern Manhattan Study includes a stroke-free community-based sample of Hispanic, black, and white participants with quantitative measurement of WMH volume (WMHV) and inflammatory biomarkers. We measured the association between Lp-PLA2, MPO, and hsCRP levels, and log-transformed WMHV after adjusting for sociodemographic and vascular risk factors.
RESULTS: The hsCRP (median, 2.42 mg/L; IQR, 1.04, 5.19), Lp-PLA2 (median, 220.97 ng/mL; IQR, 185.77, 268.05), and MPO (median, 15.14 ng/mL; IQR, 12.32, 19.69) levels were available in 527 The Northern Manhattan Study participants with WMHV data but no subclinical infarcts. Those with hsCRP in the upper quartile (Q4 >4.92 mg/L or >3 mg/L), Lp-PLA2 in Q4 (>or=264.9 ng/mL), or MPO levels in Q3 (15.04-19.39 ng/mL) or Q4 (>19.39 ng/mL) each had greater WMHV, adjusting for sociodemographic and vascular risk factors. Adjusting for all biomarkers simultaneously, WMHV was 1.3-fold greater for Lp-PLA2 levels in Q4 compared to Q1 (beta=0.28; P=0.008) and 1.25-fold greater for MPO levels above the median compared to below (beta=0.22; P=0.02), but hsCRP was not associated with WMHV.
CONCLUSIONS: Relative elevations of the inflammatory markers Lp-PLA2 and MPO were associated with a greater burden of WMH independent of hsCRP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19696417      PMCID: PMC3114944          DOI: 10.1161/STROKEAHA.109.559567

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  36 in total

1.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

2.  Retinal vessel diameters and the role of inflammation in cerebrovascular disease.

Authors:  Frank Jan de Jong; M Kamran Ikram; Jacqueline C M Witteman; Albert Hofman; Paulus T V M de Jong; Monique M B Breteler
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

3.  Lipoprotein-associated phospholipase A2 is associated with risk of dementia.

Authors:  Marieke van Oijen; Irene M van der Meer; Albert Hofman; Jacqueline C M Witteman; Peter J Koudstaal; Monique M B Breteler
Journal:  Ann Neurol       Date:  2006-01       Impact factor: 10.422

4.  Silent brain infarcts and the risk of dementia and cognitive decline.

Authors:  Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

5.  High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study.

Authors:  R L Sacco; R T Benson; D E Kargman; B Boden-Albala; C Tuck; I F Lin; J F Cheng; M C Paik; S Shea; L Berglund
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

6.  Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease.

Authors:  C R Kaneski; D F Moore; M Ries; G C Zirzow; R Schiffmann
Journal:  Neurology       Date:  2006-12-12       Impact factor: 9.910

7.  Prognostic value of myeloperoxidase in patients with chest pain.

Authors:  Marie-Luise Brennan; Marc S Penn; Frederick Van Lente; Vijay Nambi; Mehdi H Shishehbor; Ronnier J Aviles; Marlene Goormastic; Michael L Pepoy; Ellen S McErlean; Eric J Topol; Steven E Nissen; Stanley L Hazen
Journal:  N Engl J Med       Date:  2003-10-23       Impact factor: 91.245

8.  Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study.

Authors:  Sarah E Vermeer; Monika Hollander; Ewoud J van Dijk; Albert Hofman; Peter J Koudstaal; Monique M B Breteler
Journal:  Stroke       Date:  2003-04-10       Impact factor: 7.914

9.  Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome.

Authors:  Aline Hoy; Brigitte Leininger-Muller; Odette Poirier; Gérard Siest; Marion Gautier; Alexis Elbaz; Pierre Amarenco; Sophie Visvikis
Journal:  Atherosclerosis       Date:  2003-04       Impact factor: 5.162

10.  C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study.

Authors:  Jie J Cao; Chau Thach; Teri A Manolio; Bruce M Psaty; Lewis H Kuller; Paulo H M Chaves; Joseph F Polak; Kim Sutton-Tyrrell; David M Herrington; Thomas R Price; Mary Cushman
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

View more
  48 in total

Review 1.  Inflammatory mechanisms of stroke.

Authors:  Mitchell S V Elkind
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

2.  Astrocytic hypertrophy in anterior cingulate white matter of depressed suicides.

Authors:  Susana G Torres-Platas; Christa Hercher; Maria Antonietta Davoli; Gilles Maussion; Benoit Labonté; Gustavo Turecki; Naguib Mechawar
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

3.  Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-β1-42 and Hypertension.

Authors:  Omar M Al-Janabi; Christopher A Brown; Ahmed A Bahrani; Erin L Abner; Justin M Barber; Brian T Gold; Larry B Goldstein; Ronan R Murphy; Peter T Nelson; Nathan F Johnson; Leslie M Shaw; Charles D Smith; John Q Trojanowski; Donna M Wilcock; Gregory A Jicha
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS).

Authors:  Barry I Hudson; Yeseon Park Moon; Anastasia Z Kalea; Minesh Khatri; Chensy Marquez; Ann Marie Schmidt; Myunghee C Paik; Mitsuhiro Yoshita; Ralph L Sacco; Charles DeCarli; Clinton B Wright; Mitchell S V Elkind
Journal:  Atherosclerosis       Date:  2011-01-21       Impact factor: 5.162

5.  Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants.

Authors:  Naftali Raz; Yiqin Yang; Cheryl L Dahle; Susan Land
Journal:  Biochim Biophys Acta       Date:  2011-08-25

6.  C-reactive protein is associated with disability independently of vascular events: the Northern Manhattan Study.

Authors:  Mandip S Dhamoon; Ying-Kuen Cheung; Yeseon P Moon; Clinton B Wright; Joshua Z Willey; Ralph Sacco; Mitchell Sv Elkind
Journal:  Age Ageing       Date:  2017-01-15       Impact factor: 10.668

7.  Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study.

Authors:  Ashkan Shoamanesh; Sarah R Preis; Alexa S Beiser; Ramachandran S Vasan; Emelia J Benjamin; Carlos S Kase; Philip A Wolf; Charles DeCarli; Jose R Romero; Sudha Seshadri
Journal:  Neurology       Date:  2015-01-28       Impact factor: 9.910

Review 8.  Clinically asymptomatic vascular brain injury: a potent cause of cognitive impairment among older individuals.

Authors:  Charles DeCarli
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 9.  The immune system in stroke: clinical challenges and their translation to experimental research.

Authors:  Craig J Smith; Catherine B Lawrence; Beatriz Rodriguez-Grande; Krisztina J Kovacs; Jesus M Pradillo; Adam Denes
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-15       Impact factor: 4.147

10.  Lipoprotein phospholipase A2 and cerebral microbleeds in the Framingham Heart Study.

Authors:  José Rafael Romero; Sarah R Preis; Alexa S Beiser; Charles DeCarli; Dong Young Lee; Anand Viswanathan; Emelia J Benjamin; Joao Fontes; Rhoda Au; Aleksandra Pikula; Jimmy Wang; Carlos S Kase; Philip A Wolf; Michael C Irrizary; Sudha Seshadri
Journal:  Stroke       Date:  2012-09-06       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.